Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1082133

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Tackling Antimicrobial Resistance Action Plan 2019-2024, how delinking the price paid for antimicrobials from the volume sold will ensure that products produced by industry are affordable to the NHS.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228682
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228683 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106924 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1082134

registered interest
date	05/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using models that de-link the cost of research and development from the price of the final product and the volume of sales, as set out in the 2016 UN Political Declaration of the High-Level Meeting of the General Assembly on antimicrobial resistance, to ensure that new diagnostics, medicines and tools created are accessible and affordable.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	228683
answer	answer is ministerial correction date of answer 11/03/2019 answer text <p>The 2016 United Nations political declaration on antimicrobial resistance (AMR) acknowledged the importance of delinking the cost of investment in research and development on AMR from the price and volume of sales to facilitate equitable and affordable access to new products and encouraged governments to explore innovative approaches.</p><p> </p><p>It is critical that the National Health Service makes the best use of its resources. Any payment model must therefore be based on a robust evaluation of the value that a new antimicrobial product brings to patients and the public as a whole. The assessment of how much value a new antibiotic brings is highly complex and will vary considerably from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and the National Institute for Health and Care Excellence (NICE) are leading work to test innovative models that pay companies based primarily on a NICE led health technology assessment of their value to the NHS as opposed to the volumes used. This has the potential to both promote good antimicrobial stewardship and provide a much-needed incentive for the development of new antimicrobial agents that will, over time, provide value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before considering any wider change to purchasing policy. The UK represents only a small part of the global market for these drugs and we want to send a signal to the rest of the world that there are workable models to achieve the right sort of incentives for these vital medicines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 228682 question first answered 11/03/2019 18:32:38 answering member 4067 label Biography information for Steve Brine previous answer version 106925 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1052329

registered interest
date	31/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pneumococcal Diseases: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to implement the recommendations of the Joint Committee on Vaccination and Immunisation (JCVI) on reducing the dosage of pneumococcal vaccine from three to two.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	215204
answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>The Joint Committee on Vaccination and Immunisation advice on infant pneumococcal vaccination is being given full consideration and will take into account all the relevant information, including the potential public health implications such as impact on cases of pneumococcal disease, before a decision is made on whether to implement it.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:30:32 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047025

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many times he has used his powers under the Health Service Medical Supplies (Costs) Act 2017 to impose lower prices on unbranded generic or off-patent medicines sold to the NHS; and how many companies have had lowered prices as a result of those powers.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211794
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>The Department has not used its powers under the NHS Act 2006, as amended by the Health Service Medical Supplies (Costs) Act 2017, to limit prices of generic medicines. The Department continues to work with the Competition and Markets Authority on the cases they are taking forward. It has also put in place the Health Service Products (Provision and Disclosure of Information) Regulations 2018 that support its price setting powers. It is currently preparing a consultation with industry representative bodies on proposals for implementation of the price setting powers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:20:24 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047027

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the NHS' spend on unbranded generic or off-patent medicines has reduced since the Health Service Medical Supplies (Costs) Act 2017 came into force.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211795
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>Spend on generic medicines in primary care went down by 4% in 2017/18 compared to 2016/17 whilst the number of items dispensed remained broadly stable.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:21:03 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047029

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Price Caps
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many times his Department imposed financial penalties on pharmaceutical companies for failure to comply with regulations under the Medical Supplies (Costs) Act 2017 for (a) exceeding a price cap and (b) failure to record or provide requested information under a statutory scheme.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211796
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>The Department has not imposed any penalties under regulations made under any powers in the NHS Act 2006 as amended by the Health Service Medical Supplies (Costs) Act 2017.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:21:43 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047114

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an (a) assessment of the equity of the level of remuneration for special medicinal products sold to the NHS and (b) estimate of what is an equitable amount of remuneration; and if he will make a statement.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211797
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>In the period from December 2017 to November 2018, the Department spent £65 million on specials in primary care in England. That is 0.7% of spend on medicines in primary care. Spend on specials has reduced significantly since 2010 when it was £136 million. This is the consequence of a reduction in the prescribing of specials and the introduction of reimbursement prices for the most commonly prescribed specials. Specials listed with a price in the Drug Tariff incentivise community pharmacies to source the special at the lowest price possible which creates a competitive market and reduces costs. Out of the £65 million spent on specials in 2018, £20 million was spent on specials listed with a price in the Drug Tariff covering more than half of the items dispensed. The Department aims to include more specials with a reimbursement price in the Drug Tariff and seek alternative arrangements for specials that are not commonly prescribed and therefore cannot be listed with a reimbursement price. Potential savings will depend on the specials which can be listed with a Drug Tariff reimbursement price and the approach taken for those which cannot.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:22:39 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

947297

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS in England of special medicinal products over the last 12 months.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167951
answer	answer is ministerial correction date of answer 05/09/2018 answer text <p>In the most recent 12 month period for which data is available (June 2017 to May 2018) the cost of National Health Service special medicinal products dispensed in the community in England was £70.5 million down from £135.5 million in 2010.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/09/2018 10:25:43 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

947011

registered interest
date	23/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has undertaken an impact assessment on the potential beneficial effects of regulating the dispensing of special medicinal products in England.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167294
answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>We have made no such assessment. The supply of special medicinal products is regulated in the United Kingdom by the Human Medicines Regulations 2012. In addition, in England, NHS dispensing by pharmacies is regulated by the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:00:47 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

790099

registered interest
date	15/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dental Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if fewer or more claimants of universal credit will be eligible for free dental care than were under the legacy benefits systems.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	113265
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>The Department’s aim is to broadly align entitlement to help with health costs (including free National Health Service prescriptions and free NHS dental treatment) for Universal Credit recipients with those in place for the relevant legacy benefits. This is achieved by passporting Universal Credit recipients to free help with health costs where their income falls below a given earnings threshold.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 113266 question first answered 20/11/2017 17:05:26 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford